

Comparison of antitumor activity of a humanized anti-CD40 antibody and a humanized anti-CD20 antibody against Ramos lymphoma transplanted in SCID mice






Fig. 1

Comparison of antitumor activity of a murine anti-CD40 antibody (SGN-14) and a humanized anti-CD20 antibody against Ramos lymphoma transplanted in SCID mice



Start on d13
4mg/kg/3 times/wk (9 doses)

Antitumor activity of a humanized anti-CD20 antibody and humanized anti-CD40 antibody against IM9, (CD20+, CD40+Multiple myeloma) transplanted in SCID mice




00-529
110300

Days Post Tumor Implant

Start on d3
4mg/kg/3 times/wk (9 doses)

Combination of a humanized anti-CD20 antibody and a murine anti-CD40 antibody (SGN-14) for antitumor activity Against H.S. Sultan, (CD20+, CD40+Multiple myeloma) transplanted in SCID mice



Start on d3
2mg/kg 3 times/wk (9 doses)

Anti-tumor activity of a murine anti-CD40 antibody (SGN-14) and an anti-CD20 antibody (RITUXAN® brand) on RITUXAN® brand resistant Ramos Lymphoma transplanted in SCID mice




Fig. 5